Cantor Fitzgerald Maintains Overweight on Stoke Therapeutics, Lowers Price Target to $14
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has maintained an Overweight rating on Stoke Therapeutics (NASDAQ:STOK) but lowered the price target from $18 to $14.

August 08, 2023 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Stoke Therapeutics but lowered the price target from $18 to $14.
The news is directly about Stoke Therapeutics. The Overweight rating suggests that the analyst expects the stock to outperform the market, which is positive. However, the lowering of the price target from $18 to $14 indicates a reduced future valuation, which could have a negative impact. The net effect is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100